|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6450 - 0.6450|
|52 Week Range||0.6450 - 2.5000|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like...
Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To wit, the MDxHealth SA (EBR:MDXH) share price managed to fall 66% over five long years. That's not a lot o...
Want to help shape the future of investing tools? Participate in a short research study and receive a subscription valued at $60. If you want to know who really controls Read More...
Jan Groen has been the CEO of MDxHealth SA (EBR:MDXH) since 2010. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we’ll<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/is-mdxhealth-sas-ebrmdxh-ceo-being-overpaid/">Read More...</a></div>
Anyone researching MDxHealth SA (EBR:MDXH) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/what-you-must-know-about-mdxhealth-sas-ebrmdxh-market-risks-2/">Read More...</a></div>
In this article, I’m going to take a look at MDxHealth SA’s (ENXTBR:MDXH) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
MDxHealth SA’s (ENXTBR:MDXH): MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients in Belgium and internationally.Read More...